Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy
Abstract. Cancer represents a major worldwide disease burden marked by escalating incidence and mortality. While therapeutic advances persist, developing safer and precisely targeted modalities remains imperative. Nanomedicines emerges as a transformative paradigm leveraging distinctive physicochemi...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2025-08-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000003703 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849232688058204160 |
|---|---|
| author | Yue Peng Min Yu Bozhao Li Siyu Zhang Jin Cheng Feifan Wu Shuailun Du Jinbai Miao Bin Hu Igor A Olkhovsky Suping Li Yuanyuan Ji |
| author_facet | Yue Peng Min Yu Bozhao Li Siyu Zhang Jin Cheng Feifan Wu Shuailun Du Jinbai Miao Bin Hu Igor A Olkhovsky Suping Li Yuanyuan Ji |
| author_sort | Yue Peng |
| collection | DOAJ |
| description | Abstract. Cancer represents a major worldwide disease burden marked by escalating incidence and mortality. While therapeutic advances persist, developing safer and precisely targeted modalities remains imperative. Nanomedicines emerges as a transformative paradigm leveraging distinctive physicochemical properties to achieve tumor-specific drug delivery, controlled release, and tumor microenvironment modulation. By synergizing passive enhanced permeation and retention effect-driven accumulation and active ligand-mediated targeting, nanoplatforms enhance pharmacokinetics, promote tumor microenvironment enrichment, and improve cellular internalization while mitigating systemic toxicity. Despite revolutionizing cancer therapy through enhanced treatment efficacy and reduced adverse effects, translational challenges persist in manufacturing scalability, longterm biosafety, and cost-efficiency. This review systematically analyzes cutting-edge nanoplatforms, including polymeric, lipidic, biomimetic, albumin-based, peptide engineered, DNA origami, and inorganic nanocarriers, while evaluating their strategic advantages and technical limitations across three therapeutic domains: immunotherapy, chemotherapy, and radiotherapy. By assessing structure-function correlations and clinical translation barriers, this work establishes mechanistic and translational references to advance oncological nanomedicine development. |
| format | Article |
| id | doaj-art-5dfa166a04984bd98aa49a0a3dbb2ddf |
| institution | Kabale University |
| issn | 0366-6999 2542-5641 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj-art-5dfa166a04984bd98aa49a0a3dbb2ddf2025-08-21T03:04:13ZengWolters KluwerChinese Medical Journal0366-69992542-56412025-08-01138161927194410.1097/CM9.0000000000003703202508200-00005Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapyYue Peng0Min Yu1Bozhao Li2Siyu Zhang3Jin Cheng4Feifan Wu5Shuailun Du6Jinbai Miao7Bin Hu8Igor A Olkhovsky9Suping Li10Yuanyuan Ji1 Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China2 Department of Stomatology, Inner Mongolia Medical University, Hohhot, Inner Mongolia 010059, China3 CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China5 Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China3 CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China6 Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of the Chinese People’s Liberation Army (PLA) General Hospital; Medical School of Chinese PLA, Beijing 100853, China3 CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China1 Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China1 Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China7 Department of Hematology, National Research Center for Hematology, Ministry of Health, Krasnoyarsk, 660036, Russian Federation3 CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, ChinaAbstract. Cancer represents a major worldwide disease burden marked by escalating incidence and mortality. While therapeutic advances persist, developing safer and precisely targeted modalities remains imperative. Nanomedicines emerges as a transformative paradigm leveraging distinctive physicochemical properties to achieve tumor-specific drug delivery, controlled release, and tumor microenvironment modulation. By synergizing passive enhanced permeation and retention effect-driven accumulation and active ligand-mediated targeting, nanoplatforms enhance pharmacokinetics, promote tumor microenvironment enrichment, and improve cellular internalization while mitigating systemic toxicity. Despite revolutionizing cancer therapy through enhanced treatment efficacy and reduced adverse effects, translational challenges persist in manufacturing scalability, longterm biosafety, and cost-efficiency. This review systematically analyzes cutting-edge nanoplatforms, including polymeric, lipidic, biomimetic, albumin-based, peptide engineered, DNA origami, and inorganic nanocarriers, while evaluating their strategic advantages and technical limitations across three therapeutic domains: immunotherapy, chemotherapy, and radiotherapy. By assessing structure-function correlations and clinical translation barriers, this work establishes mechanistic and translational references to advance oncological nanomedicine development.http://journals.lww.com/10.1097/CM9.0000000000003703 |
| spellingShingle | Yue Peng Min Yu Bozhao Li Siyu Zhang Jin Cheng Feifan Wu Shuailun Du Jinbai Miao Bin Hu Igor A Olkhovsky Suping Li Yuanyuan Ji Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy Chinese Medical Journal |
| title | Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy |
| title_full | Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy |
| title_fullStr | Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy |
| title_full_unstemmed | Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy |
| title_short | Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy |
| title_sort | advances in nanocarrier mediated cancer therapy progress in immunotherapy chemotherapy and radiotherapy |
| url | http://journals.lww.com/10.1097/CM9.0000000000003703 |
| work_keys_str_mv | AT yuepeng advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy AT minyu advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy AT bozhaoli advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy AT siyuzhang advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy AT jincheng advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy AT feifanwu advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy AT shuailundu advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy AT jinbaimiao advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy AT binhu advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy AT igoraolkhovsky advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy AT supingli advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy AT yuanyuanji advancesinnanocarriermediatedcancertherapyprogressinimmunotherapychemotherapyandradiotherapy |